



PROBIOTIC SUPPLEMENTATION IN INFANTILE COLIC: A COMPARATIVE LITERATURE REVIEW BETWEEN BREASTFED AND FORMULA-FED INFANTS

Vira Cendana Sais¹, Erika Aini Putri², Aliffa Neta Yustisiani³, Qoniatunnisa Nuzulul Falakhi⁴,
Hafidhania Penadi⁵, Nurlinah Amalia^{6*}

¹Faculty of Medicine, Universitas Tarumanegara, Jakarta, Indonesia

²Faculty of Medicine, Universitas Brawijaya, Malang, East Java, Indonesia

³Department Medical Education, Faculty of Medicine, Universitas Brawijaya, Malang, East Java, Indonesia

⁴General Practitioner, Dr. Moewardi Hospital, Solo, Central Java, Indonesia

⁵General Practitioner, Amal Sehat Hospital, Wonogiri, Central Java, Indonesia

⁶Medical Research Center of Indonesia, Surabaya, East Java, Indonesia

ABSTRACT

Background: Infantile colic is a functional gastrointestinal disorder in infants under five months, marked by excessive, unexplained crying, and is increasingly linked to gut dysbiosis and intestinal inflammation. Probiotics may help relieve colic by modulating gut microbiota, with effects differing by feeding type. **Objective:** This study aims to evaluate the effectiveness of probiotics in managing infantile colic, with a focus on differences in outcomes between exclusively breastfed and formula-fed infants. **Methods:** This literature review identifies randomized controlled trials and cohort studies involving infants aged 0–12 months that are diagnosed with colic and receiving probiotics. The outcomes are crying frequency and duration, or symptom improvement, and compared effects between exclusively breastfed and formula-fed infants. Seven databases were searched using combinations of relevant keywords, limited to publications from the past five years. Data were synthesized using narrative qualitative analysis. **Results:** From 1,886 initially identified records, 29 studies met the eligibility criteria after screening and full-text assessment. Among the included studies, 13 investigated probiotics alone, 10 focused on breastfed infants, 4 on formula-fed infants, and 2 involved both feeding types. Most studies supported the efficacy of *Lactobacillus reuteri* DSM 17938 in reducing crying duration and frequency, particularly in breastfed infants. Formula-fed infants showed variable outcomes, potentially influenced by probiotic strain, feeding composition, and study design. **Conclusion:** Probiotics, especially *Lactobacillus reuteri*, demonstrate promising effects in alleviating colic symptoms, predominantly among breastfed infants. Feeding type may act as a modifier of probiotic efficacy, highlighting the need for tailored interventions based on nutritional context.

Keywords:

Breastfeeding,
Formula feeding,
Infantile colic,
Lactobacillus reuteri,
Probiotics

Received: 25 August 2025

Revised: 15 October 2025

Accepted: 18 October 2025

Available online: 01 May 2026

Corresponding Author:

E-mail: lina.maxlin@gmail.com

Copyright ©2026 by Authors. Published by Faculty of Medicine, Universitas Diponegoro Semarang Indonesia. This is an open access article under the CC-BY-NC-SA (<https://creativecommons.org/licenses/by-nc-sa/4.0/>).

INTRODUCTION

Infantile colic is recognized as a functional gastrointestinal disorder, characterized by recurrent and prolonged episodes of inconsolable crying or fussiness in infants younger than five months, occurring without any identifiable medical cause. According to the Rome IV criteria, the condition is defined by symptoms that persist for at least three hours per day, on a minimum of three days per week, and lasting for at least one week¹. Epidemiologically,

the prevalence of infantile colic varies considerably worldwide, with global estimates ranging from 1.9% to 19.2%, and a median prevalence of approximately 17.7% based on the Rome IV criteria². In Indonesia, a cross-sectional study involving 433 infants aged 6 weeks to 4 months reported a 16.8% prevalence of colic symptoms consistent with Rome IV criteria. The comparable rates of infantile colic in Indonesia and worldwide stress the significance of prompt diagnosis and effective treatment strategies³.



Infantile colic is generally self-limiting and resolves by six months of age, yet excessive crying in early infancy remains a leading cause of pediatric visits and emergency consultations, imposing significant healthcare burdens. Persistent crying is associated with adverse psychosocial impacts, including strained family relationships, maternal mental health disorders, early breastfeeding cessation, and, in severe cases, non-accidental injury. Current management focuses on parental reassurance, but no consensus exists on effective therapies, with most interventions showing limited efficacy, uncertain outcomes, or safety concerns¹⁴.

Emerging evidence suggests that neonatal gut microbiota alterations may influence nociceptive neurobiological pathways, contributing to infantile colic pathogenesis. Affected infants exhibit reduced microbial diversity, elevated fecal calprotectin, and increased neutrophil-derived antimicrobial peptides, indicating low-grade intestinal inflammation. Probiotics have been proposed as a preventive or therapeutic strategy by modulating central pain perception; however, their efficacy and safety are strain-specific^{5,6}.

Research by Partty et al. demonstrated that early administration of *Lactobacillus rhamnosus* GG was associated with a reduced incidence of infantile colic, alongside beneficial modulation of gut microbiota composition and inflammatory biomarkers⁷. Additionally, findings from Angela Pierina et al (2021) indicated that administration of *Lactobacillus reuteri* DSM 17938 at a daily dose of 10⁸ CFU in exclusively breastfed infants was associated with a significant reduction in symptoms of infantile colic⁸.

Lactobacillus reuteri DSM 17938 has demonstrated efficacy in alleviating infantile colic by modulating gut microbiota, reducing pro-inflammatory cytokine levels, and strengthening the intestinal barrier. It supports gastrointestinal maturation, enhances immune tolerance to dietary antigens, and produces antimicrobial compounds such as reuterin. Through interactions with Toll-like receptors, it modulates innate immunity, collectively reducing the frequency and duration of crying episodes, particularly in breastfed infants⁹.

This paper aims to assess the efficacy of probiotics in managing infantile colic, both overall and within specific feeding subgroups, namely exclusively breastfed and formula-fed infants.

METHODS

Eligibility criteria

This literature review was conducted using the PICO framework: 1) Population: infants aged 0-12 months with infantile colic; 2) Intervention: probiotics; 3) Comparison: probiotics in exclusively breastfed infants and formula-fed infants; 4) Outcomes: infantile colic symptoms, such as crying frequency, crying duration, and other signs of clinical improvement. Study Design: only randomized controlled trials (RCTs) or cohort studies were considered, and studies published in English or Indonesian.

Search strategy and screening

A literature search will be conducted using several databases, including PubMed, Cochrane Library, ScienceDirect, ProQuest, Taylor & Francis, SpringerLink, SAGE Journals, and Google Scholar. The search will incorporate appropriate keywords: "Infantile colic" AND ("Probiotic" OR "Probiotics") AND ("Breastmilk" OR "breastfed" OR "Milk formula"). Any disagreements among reviewers will be resolved through discussion.

RESULT

Study selection and identification

A total of 1,886 articles were published across six databases following the literature search. A total of 1,335 articles were excluded as ineligible by automation tools. A total of 1,212 articles were excluded for failing to meet the specified study design and inclusion criteria. Subsequently, numerous journals were excluded due to ineligible data, including review articles and books; additionally, some articles were inaccessible due to subscription barriers (n = 94). This study comprises 29 articles.

Summaries of the included studies

Among these, 13 focused on probiotics alone, 10 examined probiotics in breastfed infants, and 4 involved formula-fed infants. There are 2 studies that examined probiotics in both breastfed and formula-fed infants. Most studies supported the efficacy of *Lactobacillus reuteri* DSM 17938 in reducing crying duration and frequency, particularly in breastfed infants (**Table 1**).



Vira Cendana Sais, Erika Aini Putri, Aliffa Neta Yustisiani, Qoniattunnisa Nuzulul Falakhi, Hafidhania Penadi, Nurlinah Amalia

Table 1. Included studies

NO	AUTHOR, YEAR / STUDY	SAMPLE (PROBIOTIC/P LACEBO)	INTERVENTION	OUTCOME	
				QUANTITATIVE (PROBIOTIC & PLACEBO)	QUALITATIVE
Probiotics only					
1	Martinelli, 2017 / RCT [13]	59/57	<i>L. reuteri</i> DSM 17938	51/59 39/57	Administration of <i>L. reuteri</i> DSM 17938 are significantly more effective than simethicone in improving colic symptoms
2	Partty, 2015 / RCT [7]	81/78	<i>L. rhamnosus</i> GG (ATCC 53103) Administered via infant formula Starting from birth until 3 months of age	colic 26%/47% RR): 0.56 (95% CI: 0.33–0.95) crying duration: significantly reduced in LGG group fecal calprotectin lvl: significantly lower in probiotic group	Early-life probiotic supplementation with <i>L. rhamnosus</i> GG reduced the risk of developing colic It also favorably modified gut microbiota and inflammation markers No adverse effects reported
3	Savino, 2015 / RCT [14]	52/53 Vit D3	<i>L. reuteri</i> DSM 17938 (10 ⁸ CFU) + 400 IU vit D ₃	RR for cimetropium 0.04; simethicone 0.24; breastfeeding switch RR 0.37; fewer pediatric visits	Reduced need for medications, fewer visits; no adverse events; supports symptomatic relief
4	Savino, 2018 / RCT [15]	45/42	<i>L. reuteri</i> DSM 17938 (10 ⁸ CFU/day)	Crying time significantly reduced; ↑ RORγ/FOXP3 expression	Reductions in crying supports immune-modulatory mechanisms via T-cells
5	Maldonado-Lobón, 2021 / RCT [16]	50 per arm (Probiotic, Combo, Control)	<i>B. breve</i> CECT7263 (2×10 ⁸ CFU/day); Combo: <i>B. breve</i> + <i>L. fermentum</i> ; Simethicone 80 mg/day	Crying-time reduction: –40% to –68.5% (probiotic) vs –27% to –59% (control), significant weekly difference	Early effect, better infant sleep, improved parental mood, safe and well-tolerated
6	Piątek, 2021 / RCT [17]	54/33	9-strain synbiotic (<i>L. acidophilus</i> LA-14, <i>L. casei</i> R0215, <i>L. paracasei</i> Lp-115, <i>L. rhamnosus</i> GG, <i>L. salivarius</i> Ls-33, <i>B. lactis</i> B1-04, <i>B. bifidum</i> R0071, <i>B. longum</i>	≥50% reduction: crying days 72% vs 18%; evening crying 85% vs 39%	Multi-strain mix significantly outperformed simethicone; no adverse events



Vira Cendana Sais, Erika Aini Putri, Aliffa Neta Yustisiani, Qoniattunnisa Nuzulul Falakhi, Hafidhanian Penadi, Nurlinah Amalia

			R0175, Fructooligosaccharides (FOS) vs simethicone		
7	Ahmadipour, 2020 / RCT [18]	48/24	Synbiotic "Pedilact" (L. rhamnosus + L. reuteri + B. infantis + FOS)	Frequency ↓ significantly (P < 0.0001); Crying duration ↓ significantly (P = 0.025)	Improved quality of life, more weight gain in probiotic group; no adverse events
8	Moreno, 2024 / RCT [19]	80/80	<i>L. rhamnosus GG</i> + <i>L. reuteri DSM 17938</i> (10 ⁹ CFU/strain/day) for 21 days	Crying ↓ from 190 to 80 min/day (vs 122 in placebo), P < 0.001	Faster symptom relief; safe and well tolerated
9	Khoshnevisasi, 2022 / RCT [20]	30/30	Synbiotic (L. rhamnosus, L. reuteri, B. infantis + FOS) vs Simethicone	Crying ↓ (130 vs 80 min/day); P < 0.001	Synbiotic more effective and well tolerated than simethicone
10	Vandenplas, 2017 / RCT [21]	23/23	<i>Lactobacillus reuteri</i> SGL01 and <i>Bifidobacterium brevis</i> SGB01	Duration of crying per episode was significantly shorter (9.14 ± 5.34 vs 13.22 ± 5.29 min; p = 0.014)	Effective in reducing the number and duration of crying episodes in infants with colic
11	Basturk, 2022 / RCT [22]	20/18	<i>L. reuteri</i> DSM 17938, 1 × 10 ⁸ CFU	crying episodes: 945 ± 420 vs 1,205 ± 450 min (p = 0.041); restlessness: 1,005 vs 1,155 min (p = 0.037)	Significant reduction in crying and restlessness for both feeding types; safe and well tolerated
12	Tyrsin, 2024 / RCT [23]	45/45	<i>L. reuteri</i> DSM 17938 + FOS, 10 ⁸ CFU/day	Crying ↓ from 185 to 78 min/day (vs 122 in placebo); P < 0.001	Synbiotic more effective than placebo; symptom improvement from day 7; safe
13	Nation, 2017 / RCT [24]	85/82	<i>L. reuteri</i> DSM 17938, 1 × 10 ⁸ CFU/day	Probiotic group cried/fussed 49 min more at 1 month (P = 0.02); no difference in secondary outcomes	No clinical benefit; poor gut colonization may explain refusal; safe and well tolerated
Probiotics in the breastmilk population					
14	Savino, 2020 / RCT [25]	24/21	<i>Lactobacillus rhamnosus</i>	Probiotic (242min/day -> 104.7min/day) Placebo (247.9 min/day -> 239.6 min/day)	Reductions in crying time and faecal calprotectin levels, with increased total bacteria and <i>Lactobacillus</i> sp
15	Nocerino, 2019 / RCT [26]	40/40	<i>B. animalis</i> subsp. <i>lactis</i> BB-12 1 × 10 ⁹ CFU/day	≥50% cry reduction from wk 2; crying episodes ↓ -4.7 vs -2.3 (P < 0.05); ↑ butyrate, sIgA; ↓ calprotectin	Effective in breastfed infants; immunomodulatory effects; safe and tolerated



JURNAL KEDOKTERAN DIPONEGORO (DIPONEGORO MEDICAL JOURNAL)

Online : <http://ejournal3.undip.ac.id/index.php/medico>

E-ISSN : 2540-8844

DOI : [10.14710/dmj.v15i3.53313](https://doi.org/10.14710/dmj.v15i3.53313)

JKD (DMJ), Volume 15, Number 3, May 2026 : 210-221

Vira Cendana Sais, Erika Aini Putri, Aliffa Neta Yustisiani, Qoniattunnisa Nuzulul Falakhi, Hafidhanian Penadi, Nurlinah Amalia

16	Chen, 2021 / RCT [27]	48/42	<i>B. longum</i> KABP042 + <i>P. pentosaceus</i> KABP041, 1×10 ⁹ CFU/day	Crying decreased to 14 vs 40 min/day by Day 21; higher ≥50% responder rates; fewer episodes (p < 0.001)	Synbiotic significantly reduced crying and fussing; improved stool consistency; safe and well tolerated
17	Gerasimov, 2018 / RCT [6]	84/84	Synbiotic (<i>L. rhamnosus</i> + <i>L. reuteri</i> + FOS + vit D ₃)	Cry/fuss -163 vs -116 min/day (p = 0.019); Day 28: 142 vs 199 min/day (p < 0.05)	Significantly improved crying/fussing; safe; exclusively breastfed infants
18	Fatheree, 2017 / RCT [28]	20/10	<i>L. reuteri</i> DSM 17938, 1×10 ⁸ CFU	Cry/fuss time 300 → 140 min/day in probiotic group; no significant between-group difference	Safe in infants with neutropenia; no adverse events; underpowered for efficacy outcomes
19	Mi, 2015 / RCT [29]	21/21	<i>L. reuteri</i> DSM 17938, 1×10 ⁸ CFU	100% responders vs 15.7%; crying time : 32 vs 121 min/day (P < 0.01)	Rapid symptom relief, maternal mood improvement, safe and well tolerated
20	Baldassarre, 2018 / RCT [30]	27/26	Multi-strain probiotic (Vivomixx)	Crying: 68.4 vs 98.7 min/day by Day 21 (p=0.001); responder rate Day 21: 26/27 vs 17/26 (p=0.001)	Effective in reducing colic, improved parental QoL, safe and well tolerated
21	Savino, 2024 / RCT [31]	16/16	<i>L. reuteri</i> DSM 17938	Urinary metabolites increased post-probiotic vs placebo	Demonstrates metabolic impact; safe and well tolerated in colicky infants (Pilot RCT → mechanistic, ocusing on urinary metabolome changes, not directly measuring crying symptoms)
22	Chau, 2015 / RCT [32]	24/28	<i>L. reuteri</i> DSM 17938, 10 ⁸ CFU	Median crying: 60 vs 102 min/day (P = 0.045); total crying over 21 days: 1,719 vs 2,195 min (P = 0.028); responders: 71% vs 21% (RR = 3.3)	Significantly reduced crying/fussing; improved family QoL; well tolerated
23	Venkataraman, 2025 / RCT [33]	40/40	<i>L. reuteri</i> UBLRu-87, daily	Significant reductions in crying/fussing; high responder rates; reduced burping and facial flushing	Improved microbiome diversity; enhanced parental QoL; safe & well tolerated
Probiotics in the milk formula population					
24	Shulman, 2022 / RCT [34]	36 / 35 (PHF-LGG vs PHF)	PHF formula ± LGG (<i>L. rhamnosus</i> GG, ~10 ⁹ CFU/day)	Crying/fussing decreased similarly in both groups; no significant group differences over 3 weeks	LGG colonized the gut and altered microbiome; safe and well tolerated; no clinical advantage



JURNAL KEDOKTERAN DIPONEGORO
(DIPONEGORO MEDICAL JOURNAL)

Online : <http://ejournal3.undip.ac.id/index.php/medico>

E-ISSN : 2540-8844

DOI : [10.14710/dmj.v15i3.53313](https://doi.org/10.14710/dmj.v15i3.53313)

JKD (DMJ), Volume 15, Number 3, May 2026 : 210-221

Vira Cendana Sais, Erika Aini Putri, Aliffa Neta Yustisiani, Qoniatunnisa Nuzulul Falakhi, Hafidhanian Penadi, Nurlinah Amalia

25	Jalaludin, 2022 / Cross sectional [35]	BFI: 760/ FFI (with & without) : 2,036	Formula with pre/probiotics (varied strains), compared to formula without	IGSQ scores better in FFI+probiotics (~22.1) vs FFI-noPP (~23.4); colic and crying rates lower in	Probiotic formula group had similar GI tolerance and crying frequency as breastfed group; observational data, not causal
26	Maldonado, 2019 / RCT [36]	50/50/50	<i>B. breve</i> CECT7263 (2×10 ⁸ CFU/day) or combo <i>Lf+B.breve</i> vs simethicone	Bb: -40.3%, -59.2%, -64.5%, -68.5% by weeks 1-4; Bb + Lf: similar but later onset; control ~-27.6-59.5%	<i>B. breve</i> alone faster & more robust; improved sleep, parental mood; safe & well tolerated
27	Turco, 2020 / RCT [37]	124/117	<i>Lactobacillus reuteri</i> DSM 17938	Mean daily crying time at 28th day was significantly lower in Group B when compared to Group A [104.7 (87-122.4) versus 146.4 min (129.2-163.7), treatment effect -41.8 (95% C.I.: -66.5 to -17.1), p = 0.001]	Significantly greater reduction in daily crying time, defined as a ≥50% reduction in crying duration from baseline.
Probiotics in both populations					
28	Gigione, 2016 / RCT [38]	29/31	<i>B. breve</i> BR03 + B632 (10 ⁸ CFU/strain)	Breastmilk vs Milk formula Month 3 crying: 12.1 vs 46.7 min/day (P = 0.016); no early benefit	Reduced colic by month 3 in both populations (breastmilk and milk formula); but delayed benefit in bottle-fed infants; safe for both populations
29	Zoham, 2019 / RCT [39]	33/32	Pedilact synbiotic (<i>B. infantis</i> , <i>L. reuteri</i> , <i>L. rhamnosus</i>)	Breastmilk vs Milk formula Daily crying/fuss episodes, crying days, and crying duration significantly reduced (P ≤ 0.032 by day 21; P ≤ 0.001 by day 30)	Effective in mixed-fed infants; early symptom relief; safe



DISCUSSION

Probiotics are live microorganisms that, when administered in adequate amounts, confer health benefits to the host by supporting intestinal microbiota balance, which is essential for overall health. Probiotics support host health by influencing immune system activity, strengthening the intestinal barrier, generating antimicrobial compounds, and inhibiting pathogen colonization by competing for attachment sites and available nutrients in the gut. These mechanisms collectively support digestive health and may provide therapeutic benefits in various disorders, including inflammatory, allergic, and infectious diseases. Common genera used as probiotics include *Lactobacillus*, *Bifidobacterium*, and certain *Saccharomyces* species¹⁰.

Probiotics have been extensively investigated across various gastrointestinal disorders. Probiotic administration was associated with a reduced incidence of necrotizing enterocolitis (NEC) in pediatric populations. Furthermore, a meta-analysis by Rao Huang et al. revealed that in the context of pediatric acute diarrhea, adjunctive probiotic therapy was effective in reducing symptom duration¹¹. Probiotic led to significant improvements in among patients with irritable bowel syndrome (IBS)¹².

Various studies have shown the benefits of using probiotics to support digestive health and boost children immunity. Colic has been associated with gut dysbiosis, an imbalance in the gut bacteria that can lead to inflammation and digestive issues¹⁸. As for the efficacy of probiotics, *Lactobacillus acidophilus* (HA122), *Lactobacillus reuteri* NCIMB 30351 could promote a healthy gut which can help reduce inflammation and support better digestion¹³. Another *Lactobacillus* species like *Lactobacillus reuteri* DSM 17938 has been shown to have a calming effect on the gut, improving gut motility and reducing bloating²². Other probiotics like *Bifidobacterium breve* also help restore the balance of beneficial bacteria in the intestines^{21,36}.

The probiotic treatment positively affected the expression of ROR γ and FOXP3, both of which are involved in maintaining immune tolerance and regulating inflammation¹⁵. *Lactobacillus reuteri* led to a reduction in inflammatory markers in the gut. *Lactobacillus rhamnosus* GG helps regulate the gut microbiota by promoting the growth of beneficial bacteria, which in turn helps reduce gut inflammation

and improve digestion. Probiotics' effects on the microbiome likely contributed to improved digestion and a decrease in gut-related discomfort, which are common issues in infants with colic⁷. The preventive effect of *Lactobacillus reuteri* DSM 17938 was one of the most significant findings of study by Savino which infants who received the probiotic early had a lower incidence of colic symptoms compared to those who did not receive it¹⁴.

Microbiota engage with the gut-brain axis, influencing gut sensory and motor functions by transmitting and receiving various signals to and from the brain. A modified microbiota colonization of the gastrointestinal tract may alter the bidirectional interrelation, potentially contributing to the pathogenesis of infantile colic. According to this, microbiota modulation through probiotic administration may be beneficial³⁰.

Infants receiving probiotics exhibited a greater increase in all immunity biomarkers (HBD-2, LL-37, and sIgA) compared to those in the placebo group, indicating that probiotics may have an immunomodulatory effect on the infant gut [40]. Probiotics influence the proliferation of human peripheral blood mononuclear cells and the expression of cytokines, providing protective effects against gastrointestinal infections in infants and children. Bifidobacteria inhibit Proteobacteria and promote butyrate production in infants experiencing colic. Bifidobacteria do not produce butyrate directly; however, by engaging in cross-feeding with other commensal bacteria⁴¹, they can enhance butyrate levels, potentially influencing various aspects of gut physiology. Butyrate influences intestinal transit time, alters visceral and central pain perception, affects the gut-brain axis, and demonstrates significant anti-inflammatory properties^{42,43}.

However, some studies noted a high placebo response, such as Fatheree et al. (2017)²⁸, where 66% of the placebo group also improved, and Giglione et al. (2016)³⁸, which found no significant difference ($P = 0.14$) in outcomes between breastfed infants receiving probiotics versus controls. Nocerino et al. (2019) stated that qualitatively, probiotic use was generally safe and well tolerated, with improvements observed in stool consistency, gut inflammation markers (e.g., fecal calprotectin), and immune parameters (e.g., sIgA, defensins)²⁶. Some studies also examined maternal dietary modifications, such as



cow's milk elimination, as potential enhancers of probiotic efficacy [7]. While spontaneous resolution of colic over time was acknowledged in several trials, strains such as *L. reuteri* and *B. animalis* BB-12 remain consistently associated with clinically meaningful reductions in colic symptoms, especially among exclusively breastfed infants. Further studies are warranted to elucidate potential synergistic effects between probiotic supplementation and breast milk components³⁹.

When comparing study methodologies, most non-significant trials involved formula-fed or mixed-fed infants, with shorter intervention durations (typically 14–21 days) and lower probiotic doses (around 10^8 CFU/day). In contrast, studies reporting significant improvements especially among exclusively breastfed infants administered higher doses (10^9 – 10^{10} CFU/day) for at least four weeks, often using *Lactobacillus reuteri* DSM 17938. Differences in probiotic colonization have been attributed to gut environmental factors: breastfed infants possess higher levels of human milk oligosaccharides (HMOs) and *Bifidobacterium*, which may enhance probiotic survival and efficacy. Conversely, the absence of these synergistic substrates in formula-fed infants may partly explain the delayed or absent therapeutic responses observed in some studies^{6,7,13–39}.

Several studies have explored the integration of probiotics into infant formula to assess whether it yields outcomes comparable to breastfed infants or standard formula feeding³⁶. Evidence from randomized controlled trials and observational studies indicates that probiotic-enriched formulas can reduce colic symptoms more effectively than standard formulas, as shown by Maldonado et al. (2019) and the Happy Tummy Consortium (2022), which reported significant decreases in crying time, improved sleep quality, and better gastrointestinal tolerance³⁵. However, when comparing formula-fed and breastfed infants receiving probiotics, the latter group demonstrates greater and faster symptom relief²⁴. Studies by Savino et al. (2015, 2018) and Fatheree et al. (2017) reported notable reductions in crying duration and higher parental satisfaction among breastfed infants, whereas Nation et al. (2017) found limited probiotic colonization and no significant improvement in formula-fed infants. These findings suggest that the breastfed gut environment enriched

with human milk oligosaccharides and immunomodulatory compounds may enhance probiotic colonization and therapeutic efficacy^{14,15,28}.

This literature review provides a comprehensive synthesis of current evidence regarding the use of probiotics for managing infantile colic, with a unique focus on feeding type as a potential modifier of treatment efficacy. A key strength of this review lies in its rigorous selection criteria, including only randomized controlled trials and cohort studies published within the last five years, ensuring relevance and methodological quality. The use of multiple major databases and independent screening by multiple reviewers also enhances the reliability of the findings. However, the review is limited by the heterogeneity of included studies in terms of probiotic strains, dosages, treatment durations, and outcome measures, which precludes quantitative meta-analysis. Additionally, the limited number of studies involving formula-fed infants restricts the ability to draw firm conclusions for this subgroup. Language restrictions and potential publication bias may also affect the generalizability of the findings.

CONCLUSION

This literature review concludes that probiotic supplementation, particularly with *Lactobacillus reuteri* DSM 17938, is associated with a reduction in the frequency and duration of crying episodes in infants diagnosed with colic. The therapeutic effect appears more consistent and pronounced in exclusively breastfed infants compared to their formula-fed counterparts. These findings suggest that the mode of infant feeding may influence the clinical efficacy of probiotics in managing colic, likely through its impact on gut microbiota composition and immune modulation. Future research should aim to standardize probiotic strains, dosages, and feeding regimens to optimize treatment outcomes across diverse infant populations.

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

FUNDING

There is no funding for this article.



AUTHOR CONTRIBUTIONS

Vira Cendana Sais and Nurlinah Amalia contributed to the conception and design of the study, as well as the technical supervision. Vira Cendana Sais, Erika Aini Putri, Aliffa Neta Yustisiani, Qoniatunnisa Nuzulul Falakhi, and Hafidhania Penadi extracted the data. Nurlinah Amalia performed an interpretation result and provided technical supervision. Erika Aini Putri, Aliffa Neta Yustisiani, Qoniatunnisa Nuzulul Falakhi, and Hafidhania Penadi drafted the manuscript. All authors critically revised the manuscript for important intellectual content, approved the final version, and agreed to be accountable for all aspects of the work.

ACKNOWLEDGMENTS

We extend our sincere gratitude to Medhub Academy, Jakarta, Indonesia for valuable support.

REFERENCES

1. Zeevenhooven J, Koppen IJN, Benninga MA. The New Rome IV Criteria for Functional Gastrointestinal Disorders in Infants and Toddlers. *Pediatr Gastroenterol Hepatol Nutr* 2017;20:1. <https://doi.org/10.5223/pghn.2017.20.1.1>.
2. Muhandi L, Aw MM, Hasosah M, Ng RT, Chong SY, Hegar B, et al. A Narrative Review on the Update in the Prevalence of Infantile Colic, Regurgitation, and Constipation in Young Children: Implications of the ROME IV Criteria. *Front Pediatr* 2022;9. <https://doi.org/10.3389/fped.2021.778747>.
3. Lestari LA, Rizal AN, Damayanti W, Wibowo Y, Ming C, Vandenplas Y. Prevalence and Risk Factors of Functional Gastrointestinal Disorders in Infants in Indonesia. *Pediatr Gastroenterol Hepatol Nutr* 2023;26:58. <https://doi.org/10.5223/pghn.2023.26.1.58>.
4. Ellwood J, Draper-Rodi J, Carnes D. Comparison of common interventions for the treatment of infantile colic: a systematic review of reviews and guidelines. *BMJ Open* 2020;10:e035405. <https://doi.org/10.1136/bmjopen-2019-035405>.
5. Indrio F, Dargenio VN, Francavilla R, Szajewska H, Vandenplas Y. Infantile Colic and Long-Term Outcomes in Childhood: A Narrative Synthesis of the Evidence. *Nutrients* 2023;15:615. <https://doi.org/10.3390/nu15030615>.
6. Gerasimov S, Gantzel J, Dementieva N, Schevchenko O, Tsitsura O, Guta N, et al. Role of *Lactobacillus rhamnosus* (FloraActive™) 19070-2 and *Lactobacillus reuteri* (FloraActive™) 12246 in Infant Colic: A Randomized Dietary Study. *Nutrients* 2018;10:1975. <https://doi.org/10.3390/nu10121975>.
7. Pärtty A, Lehtonen L, Kalliomäki M, Salminen S, Isolauri E. Probiotic *Lactobacillus rhamnosus* GG therapy and microbiological programming in infantile colic: a randomized, controlled trial. *Pediatr Res* 2015;78:470–5. <https://doi.org/10.1038/pr.2015.127>.
8. dos Reis Buzzo Zermiani AP, de Paula Soares ALPP, da Silva Guedes de Moura BL, Miguel ERA, Lopes LDG, de Carvalho Scharf Santana N, et al. Evidence of *Lactobacillus reuteri* to reduce colic in breastfed babies: Systematic review and meta-analysis. *Complement Ther Med* 2021;63:102781. <https://doi.org/10.1016/j.ctim.2021.102781>.
9. Savino F, Galliano I, Savino A, Daprà V, Montanari P, Calvi C, et al. *Lactobacillus reuteri* DSM 17938 Probiotics May Increase CC-Chemokine Receptor 7 Expression in Infants Treated With for Colic. *Front Pediatr* 2019;7. <https://doi.org/10.3389/fped.2019.00292>.
10. Plaza-Diaz J, Ruiz-Ojeda FJ, Gil-Campos M, Gil A. Mechanisms of Action of Probiotics. *Advances in Nutrition* 2019;10:S49–66. <https://doi.org/10.1093/advances/nmy063>.
11. Huang R, Xing H-Y, Liu H-J, Chen Z-F, Tang B-B. Efficacy of probiotics in the treatment of acute diarrhea in children: a systematic review and meta-analysis of clinical trials. *Transl Pediatr* 2021;10:3248–60. <https://doi.org/10.21037/tp-21-511>.
12. Repa A, Thanhaeuser M, Endress D, Weber M, Kreissl A, Binder C, et al. Probiotics (*Lactobacillus acidophilus* and *Bifidobacterium bifidum*) prevent NEC in



- VLBW infants fed breast milk but not formula. *Pediatr Res* 2015;77:381–8. <https://doi.org/10.1038/pr.2014.192> .
13. Martinelli M, Ummarino D, Giugliano FP, Sciorio E, Tortora C, Bruzzese D, et al. Efficacy of a standardized extract of *Matricariae chamomilla* L., *Melissa officinalis* L. and tyndallized *Lactobacillus acidophilus* (<scp>HA</scp> 122) in infantile colic: An open randomized controlled trial. *Neurogastroenterology & Motility* 2017;29. <https://doi.org/10.1111/nmo.13145> .
 14. Savino F, Ceratto S, Poggi E, Cartosio ME, Cordero di Montezemolo L, Giannattasio A. Preventive effects of oral probiotic on infantile colic: a prospective, randomised, blinded, controlled trial using *Lactobacillus reuteri* DSM 17938. *Benef Microbes* 2015;6:245–52. <https://doi.org/10.3920/BM2014.0090> .
 15. Savino F, Garro M, Montanari P, Galliano I, Bergallo M. Crying Time and ROR γ /FOXP3 Expression in *Lactobacillus reuteri* DSM17938-Treated Infants with Colic: A Randomized Trial. *J Pediatr* 2018;192:171–177.e1. <https://doi.org/10.1016/j.jpeds.2017.08.062> .
 16. Maldonado-Lobón JA, Blanco-Rojo R, Maldonado J, Ali MA, Almazán MV, Suanes-Cabello A, et al. Efficacy of *Bifidobacterium breve* CECT7263 for infantile colic treatment: an open-label, parallel, randomised, controlled trial. *Benef Microbes* 2021;12:55–68. <https://doi.org/10.3920/BM2020.0105> .
 17. Piątek J, Bernatek M, Krauss H, Wojciechowska M, Chęcińska-Maciejewska Z, Kaczmarek P, et al. Effects of a nine-strain bacterial synbiotic compared to simethicone in colicky babies – an open-label randomised study. *Benef Microbes* 2021;12:249–58. <https://doi.org/10.3920/BM2020.0160> .
 18. Ahmadipour S, Fallahi A, Rahmani P. Probiotics for infantile colic. *Clin Nutr Exp* 2020;31:1–7. <https://doi.org/10.1016/j.yclnex.2020.04.001> .
 19. Moreno-Villares JM, Andrade-Platas D, Soria-López M, Colomé-Rivero G, Catalan Lamban A, Martinez-Figueroa MG, et al. Comparative efficacy of probiotic mixture *Bifidobacterium longum* KABP042 plus *Pediococcus pentosaceus* KABP041 vs. *Limosilactobacillus reuteri* DSM17938 in the management of infant colic: a randomized clinical trial. *Eur J Pediatr* 2024;183:5371–81. <https://doi.org/10.1007/s00431-024-05806-x> .
 20. Khoshnevisasl P, Sadeghzadeh M, Kamali K, Hasanlo M. The effect of symbiotic in the treatment of infantile colic. *Journal of Research in Medical Sciences* 2022;27:42. https://doi.org/10.4103/jrms.jrms_128_21 .
 21. Vandenas Y, Bacarea A, Marusteri M, Bacarea V, Constantin M, Manolache M. Efficacy and safety of APT198K for the treatment of infantile colic: a pilot study. *J Comp Eff Res* 2017;6:137–44. <https://doi.org/10.2217/cer-2016-0059> .
 22. Basturk. Investigation of the Effectiveness of *Lactobacillus reuteri* DSM 17938 in the Treatment of Infantile Colic: A Double-blind Placebo-controlled Randomised Study. *HK J Paediatric* 2022.
 23. Tyrsin OY, Tyrsin DY, Nemenov DG, Ruzov AS, Odintsova VE, Koshechkin SI, et al. Effect of *Lactobacillus reuteri* NCIMB 30351 drops on symptoms of infantile functional gastrointestinal disorders and gut microbiota in early infants: Results from a randomized, placebo-controlled clinical trial. *Eur J Pediatr* 2024;183:2311–24. <https://doi.org/10.1007/s00431-024-05473-y> .
 24. Nation ML, Dunne EM, Joseph SJ, Mensah FK, Sung V, Satzke C, et al. Impact of *Lactobacillus reuteri* colonization on gut microbiota, inflammation, and crying time in infant colic. *Sci Rep* 2017;7:15047. <https://doi.org/10.1038/s41598-017-15404-7> .
 25. Savino F, Montanari P, Galliano I, Daprà V, Bergallo M. *Lactobacillus rhamnosus* GG (ATCC 53103) for the Management of Infantile Colic: A Randomized Controlled Trial. *Nutrients* 2020;12:1693. <https://doi.org/10.3390/nu12061693> .
 26. Nocerino R, De Filippis F, Cecere G, Marino A, Micillo M, Di Scala C, et al. The therapeutic efficacy of *Bifidobacterium animalis* subsp. *lactis* BB-12[®] in infant colic: A randomised, double blind, placebo-controlled trial. *Aliment*



- Pharmacol Ther 2020;51:110–20.
<https://doi.org/10.1111/apt.15561> .
27. Chen K, Zhang G, Xie H, You L, Li H, Zhang Y, et al. Efficacy of Bifidobacterium animalis subsp. lactis, BB-12® on infant colic – a randomised, double-blinded, placebo-controlled study. *Benef Microbes* 2021;12:531–40.
<https://doi.org/10.3920/BM2020.0233> .
28. Fatheree NY, Liu Y, Taylor CM, Hoang TK, Cai C, Rahbar MH, et al. Lactobacillus reuteri for Infants with Colic: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. *J Pediatr* 2017;191:170-178.e2.
<https://doi.org/10.1016/j.jpeds.2017.07.036> .
29. Mi G-L, Zhao L, Qiao D-D, Kang W-Q, Tang M-Q, Xu J-K. Effectiveness of Lactobacillus reuteri in infantile colic and colicky induced maternal depression: a prospective single blind randomized trial. *Antonie Van Leeuwenhoek* 2015;107:1547–53.
<https://doi.org/10.1007/s10482-015-0448-9> .
30. Baldassarre M, Di Mauro A, Tafuri S, Rizzo V, Gallone M, Mastromarino P, et al. Effectiveness and Safety of a Probiotic-Mixture for the Treatment of Infantile Colic: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial with Fecal Real-Time PCR and NMR-Based Metabolomics Analysis. *Nutrients* 2018;10:195.
<https://doi.org/10.3390/nu10020195> .
31. Savino F, Passerini M, Gambarino S, Clemente A, Dini M, Montanari P, et al. White blood cells, TNF- α , and interleukin-6 in subjects with infantile colic treated with Lactobacillus reuteri DSM 17938 (ATCC 53103): a randomised prospective study. *Benef Microbes* 2024;15:417–29.
<https://doi.org/10.1163/18762891-bja00010> .
32. Chau K, Lau E, Greenberg S, Jacobson S, Yazdani-Brojeni P, Verma N, et al. Probiotics for Infantile Colic: A Randomized, Double-Blind, Placebo-Controlled Trial Investigating Lactobacillus reuteri DSM 17938. *J Pediatr* 2015;166:74-78.e1.
<https://doi.org/10.1016/j.jpeds.2014.09.020> .
33. Venkataraman R, Kotyal Basvanyappa M, Samanta B, Yadla M, Ravi NA, Neelamraju J, et al. Efficacy of Limosilactobacillus reuteri UBLRu-87 in Infantile Colic and Its Symptoms: A Double-Blind, Placebo-Controlled Study. *Cureus* 2025.
<https://doi.org/10.7759/cureus.81856> .
34. Shulman RJ, Chichlowski M, Orozco FG, Harris CL, Wampler JL, Bokulich NA, et al. Infant behavioral state and stool microbiome in infants receiving Lactocaseibacillus rhamnosus GG in formula: randomized controlled trial. *BMC Pediatr* 2022;22:580.
<https://doi.org/10.1186/s12887-022-03647-x> .
35. Jalaludin MY, Taher SWB, Kiau HB, Hashim SB, Yusof MB, Khew LW, et al. Infant feeding practice and gastrointestinal tolerance: a real-world, multi-country, cross-sectional observational study. *BMC Pediatr* 2022;22:714. <https://doi.org/10.1186/s12887-022-03763-8> .
36. Maldonado J, Gil-Campos M, Maldonado-Lobón JA, Benavides MR, Flores-Rojas K, Jaldo R, et al. Evaluation of the safety, tolerance and efficacy of 1-year consumption of infant formula supplemented with Lactobacillus fermentum CECT5716 Lc40 or Bifidobacterium breve CECT7263: a randomized controlled trial. *BMC Pediatr* 2019;19:361. <https://doi.org/10.1186/s12887-019-1753-7> .
37. Turco R, Russo M, Bruzzese D, Staiano A. Efficacy of a partially hydrolysed formula, with reduced lactose content and with Lactobacillus reuteri DSM 17938 in infant colic: A double blind, randomised clinical trial. *Clinical Nutrition* 2021;40:412–9.
<https://doi.org/10.1016/j.clnu.2020.05.048> .
38. Giglione E, Prodam F, Bellone S, Monticone S, Beux S, Marolda A, et al. The Association of Bifidobacterium breve BR03 and B632 is Effective to Prevent Colics in Bottle-fed Infants. *J Clin Gastroenterol* 2016;50:S164–7.
<https://doi.org/10.1097/MCG.0000000000000693> .
39. Habibi Zoham M, Zafar F, Malekiantaghi A, Ettehadi R, Jazayeri SB, Eftekhari K. Evaluation of the Efficacy of Probiotics in the Treatment of Infantile Colic; a Randomized, Double Blind; Placebo Controlled Trial. *Acta Med Iran* 2020.
<https://doi.org/10.18502/acta.v57i7.2325> .



40. Berni Canani R, De Filippis F, Nocerino R, Laiola M, Paparo L, Calignano A, et al. Specific Signatures of the Gut Microbiota and Increased Levels of Butyrate in Children Treated with Fermented Cow's Milk Containing Heat-Killed *Lactobacillus paracasei* CBA L74. *Appl Environ Microbiol* 2017;83.
<https://doi.org/10.1128/AEM.01206-17> .
41. Savino F, Quartieri A, De Marco A, Garro M, Amaretti A, Raimondi S, et al. Comparison of formula-fed infants with and without colic revealed significant differences in total bacteria, *Enterobacteriaceae* and faecal ammonia. *Acta Paediatr* 2017;106:573–8.
<https://doi.org/10.1111/apa.13642> .
42. Sanders ME, Merenstein DJ, Reid G, Gibson GR, Rastall RA. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. *Nat Rev Gastroenterol Hepatol* 2019;16:605–16.
<https://doi.org/10.1038/s41575-019-0173-3> .
43. Stilling RM, van de Wouw M, Clarke G, Stanton C, Dinan TG, Cryan JF. The neuropharmacology of butyrate: The bread and butter of the microbiota-gut-brain axis? *Neurochem Int* 2016;99:110–32.
<https://doi.org/10.1016/j.neuint.2016.06.011> .